What is Tempus?
Tempus AI, Inc. operates at the intersection of artificial intelligence, machine learning, and advanced genomic diagnostics. The company has built one of the world's largest libraries of clinical and molecular data, enabling medical practitioners to move away from traditional, one-size-fits-all treatments toward highly tailored, precision-based therapeutic models. By unifying disparate patient history fragments with deep molecular sequencing, the platform generates comprehensive, multimodal profiles that identify invisible genetic patterns and therapeutic correlations. This sophisticated data engine empowers clinicians to uncover hidden diagnostic risks and forecast patient responses to diverse chemical interventions, effectively bridging the gap between raw data and actionable clinical insights.
How much funding has Tempus raised?
Tempus has raised a total of $2.1B across 12 funding rounds:
Series B
$50M
Series C
$70M
Series D
$80M
Series E
$110M
Series F
$200M
Multiple Rounds
$550M
Other Financing Round
$275M
Stock Offering
$410.7M
Debt
$300M
Series B (2017): $50M, investors not publicly disclosed
Series C (2017): $70M supported by Revolution Growth and New Enterprise Associates
Series D (2018): $80M featuring T. Rowe Price and Revolution Growth
Series E (2018): $110M backed by New Enterprise Associates, T. Rowe Price, Revolution Growth, and Baillie Gifford
Series F (2019): $200M with participation from Baillie Gifford, New Enterprise Associates, T. Rowe Price, Novo Holdings, Franklin Templeton Investments, and Revolution Growth
Series G (2020): $200M led by Novo Holdings, Franklin Templeton, T. Rowe Price, Baillie Gifford, and NEA
Other Financing Round (2020): $100M, investors not publicly disclosed
Debt (2020): $250M, investors not publicly disclosed
Other Financing Round (2022): $275M backed by Ares Capital
Stock Issuance/Offering (2024): $410.7M, investors not publicly disclosed
Debt (2025): $300M led by Ares Management Corporation
Key Investors in Tempus
T. Rowe Price
A global asset management organization providing investment solutions across equities and fixed income, known for its long-term investment perspectives and fundamental analysis.
New Enterprise Associates
A prominent venture capital firm established in 1977, focused on partnering with entrepreneurs to build transformative businesses across various technology sectors.
Revolution Growth
A venture capital firm that invests in transformative technologies and supports visionary founders, with a strategic focus on innovation beyond traditional tech hubs.
What's next for Tempus?
With the support of this major strategic investment, Tempus is well-positioned to accelerate its expansion into new therapeutic areas and enhance its proprietary neural network capabilities. The company's focus remains on scaling its data-driven platform to further integrate into the global healthcare ecosystem, ultimately improving patient outcomes through more accurate, data-backed decision-making. As the enterprise matures, it is expected to continue its leadership in the precision medicine sector, utilizing its robust financial foundation to drive long-term value for both clinical partners and the broader medical community.
See full Tempus company page
